Fu Zheng Jie Du Hua Yu Principle For Treatment Of Severe HBV Related Hepatocellular Carcinoma (FZJDHYPFTOSHBVHCC)

Early Phase 1UnknownNCT05152498

Beijing Ditan Hospital142 enrolled

Overview

The treatment of HBV related hepatocellular carcinoma has always been a worldwide problem. The aim of this study is to alleviate the progression of hepatitis B related hepatocellular carcinoma by the Chinese medicine "Fu Zheng Jie Du Hua Yu" Principle.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

142

Conditions

Hepatocellular Carcinoma

Interventions

Fu Zheng Jie Du Hua Yu therapyDRUG

Fu Zheng Jie Du Hua Yu is a Chinese herbal compound

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Meet the criteria of hepatocellular carcinoma * Ages Eligible for Study: ≤75 years old; * Informed consent from the patient. Exclusion Criteria: * Serious problem of heart, lung, or kidney with severe dysfunction; * Pregnant or child breast feeding women; * Mental or cognitive disorders; * Participating in other drug trials; * Who are allergic to the study drug

Locations (1)

Zhiyun Yang

Beijing, Beijing Municipality, China

RECRUITING

Outcomes

Primary Outcomes

Time to Progression

Time frame: 1 year

Secondary Outcomes

overall survival

Time frame: 1 year

progression-free survival

Time frame: 1 year

complete response

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.